HKPD

HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratification of the appointment of Onestop Assurance PAC as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026; Proposal No. 3: The increase of the authorized share capital of the Company from US$100,000 divided into 100,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001. Proposal No. 4: The re-designation and re-classification from ordinary shares of a single class to Class A ordinary shares and Class B ordinary shares. Proposal No. 5: The approval and implementation of the Reverse Share Split and Share Consolidation of the Company’s issued and outstanding Ordinary Shares. Proposal No. 6: The Company’s name be changed from “Hong Kong Pharma Digital Technology Holdings Limited” to “Cellyan Biotechnology Co., Ltd” and the Company’s foreign name be changed from “港药数字科技控股有限公司” to “生研生物公司”. Proposal No. 7: The fourth amended and restated memorandum and articles of association of the Company be adopted. Proposal No. 8: The repurchase by the Company of 7,150,000 Class A Ordinary Shares registered in the name of TUTU Business Services Limited and issue of Class B Ordinary Shares; Proposal No. 9: The adoption and approval of the Hong Kong Pharma Digital Technology Holdings Limited 2025 Equity Incentive Plan; For the full text of the above proposals passed and approved at the 2025 AGM, refer to the Form 6-K furnished to the SEC on December 17, 2025. About Hong Kong Pharma Digital Technology Holdings Limited Hong Kong Pharma Digital Technology Holdings Limited offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain...

HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023. Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023. Revenue Breakdown: Revenue Breakdown: Six Months ended September 30, 2024 Six Months ended September 30, 2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement and distribution 4,759,301 2,346,931 Consignment sales and other revenue 2,210 15,327 Total Revenue $ 11,091,189 $ 7,009,209 - Supply Chain Services: $6,329,678, up 36.3% from $4,646,951 for the same period in 2023. - Procurement and Distribution: $4,759,301, a 102.7% increase from $2,346,931 for the same period in 2023. - Consignment Sales and Other Revenue: $2,210, down from $15,327 for the same period in 2023. Gross Profit: The gross profit for the period was $1,905,603, a 42.6% increase from $1,335,988 for the same period in 2023. Gross Profit: The gross profit for the period was $1,905,603, a 42.6% increase from $1,335,988 for the same period in 2023. Total Expenses Total Expenses: Increased to $10,066,706 for the six months ended September 30, 2024, up from $6,667,999 for the same period last year. Total Expenses: Increased to $10,066,706 for the six months ended September 30, 2024, up from $6,667,999 for the same period last year. Six Months ended September 30, 2024 Six Months ended September 30, 2023 Changes in inventories of merchandised goods $ 4,513,873 $ 2,171,361 Storage cost 530,012 463,412 Transportation cost 2,619,599 1,046,455 Consumption of packing material 514,714 515,594 Depreciation and amortization 30,153 31,727 Labor cost 1,318,041 1,589,164 Outsourcing expenses 328,755 202,169 Others 211,559 648,117 Total cost of sales, selling, general and administrative expenses $ 10,066,706 $ 6,667,999 Net Income Net Income: The Company achieved a net income of $828,559, a 232.6% increase compared to $249...